Pathogenic role of anti–signal recognition protein and anti–3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies

Annals of Neurology

Volumn 81, Issue 4, 2017, Pages 538-548

  Arouche Delaperche, Louiza ^a   Allenbach, Yves ^a,b   Amelin, Damien ^a   Preusse, Corinna ^c   Mouly, Vincent ^a   Mauhin, Wladimir ^a   Tchoupou, Gaelle Dzangue ^a   Drouot, Laurent ^d   Boyer, Olivier ^d   Stenzel, Werner ^c   Butler Browne, Gillian ^a   Benveniste, Olivier ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARATE COA REDUCTASE ANTIBODY; ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; SIGNAL RECOGNITION PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; SIGNAL RECOGNITION PARTICLE;

ANTIBODY TITER; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOPATHOLOGY; IN VITRO STUDY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE REGENERATION; MYOBLAST; MYOSITIS; MYOTUBE; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; ATROPHY; AUTOIMMUNE DISEASE; CELL CULTURE TECHNIQUE; IMMUNOLOGY; MUSCLE DISEASE; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; SKELETAL MUSCLE CELL; TISSUE BANK;

ATROPHY; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CELL CULTURE TECHNIQUES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MUSCLE FIBERS, SKELETAL; MUSCULAR DISEASES; NECROSIS; REGENERATION; SIGNAL RECOGNITION PARTICLE; TISSUE BANKS;

EID: 85018792551     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24902     Document Type: Article

References (53)

1. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014;93:150–157.
2. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713–721.
3. Hengstman GJD, ter Laak HJ, Egberts WTMV, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635–1638.
4. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC International Workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 2004;14:337–345.
5. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med 2016;374:664–669.
6. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol 2013;26:554–560.
7. Miller T, Al-Lozi M, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420–428.
8. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011;63:1961–1971.
9. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64:4087–4093.
10. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients [Internet]. Orphanet J Rare Dis 2015;10:61.
11. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43:49–54.
12. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015;2:e124.
13. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704–1708.
14. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001;98:14440–14445.
15. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology 2008;23:160–170.
16. Le Grand F, Rudnicki MA. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol 2007;19:628–633.
17. Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003;113:483–494.
18. Drouot L, Allenbach Y, Jouen F, et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 2014;16:R39.
19. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011;63:1961–1971.
20. Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies. Am J Pathol 2016;186:691–700.
21. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671–675.
22. Zerbe N, Hufnagl P, Schlüns K. Distributed computing in image analysis using open source frameworks and application to image sharpness assessment of histological whole slide images. Diagn Pathol 2011;6(suppl 1):S16.
23. Brooke MH, Engel WK. The histographic analysis of human muscle biopsies with regard to fiber types. 2. Diseases of the upper and lower motor neuron. Neurology 1969;19:378–393.
24. Briguet A, Courdier-Fruh I, Foster M, et al. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 2004;14:675–682.
25. Bigot A, Jacquemin V, Debacq-Chainiaux F, et al. Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol Cell 2008;100:189–199.
26. Garton F, Seto JT, North KN, Yang N. Validation of an automated computational method for skeletal muscle fibre morphometry analysis. Neuromuscul Disord 2010;20:540–547.
27. Feferman T, Maiti PK, Berrih-Aknin S, et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 2005;174:5324–5331.
28. Zhang L, Pan J, Dong Y, et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab 2013;18:368–379.
29. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II–induced muscle wasting. J Am Soc Nephrol 2009;20:604–612.
30. Li Y-P, Chen Y, John J, et al. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362–370.
31. Jacquemin V, Furling D, Bigot A, et al. IGF-1 induces human myotube hypertrophy by increasing cell recruitment. Exp Cell Res 2004;299:148–158.
32. Römisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006;8:R39.
33. Luirink J, Sinning I. SRP-mediated protein targeting: structure and function revisited. Biochim Biophys Acta 2004;1694:17–35.
34. Saraogi I, Shan S. Molecular mechanism of co-translational protein targeting by the signal recognition particle. Traffic 2011;12:535–542.
35. Schwartz T, Blobel G. Structural basis for the function of the β subunit of the eukaryotic signal recognition particle receptor. Cell 2003;112:793–803.
36. McNally AK, Anderson JM. Multinucleated giant cell formation exhibits features of phagocytosis with participation of the endoplasmic reticulum. Exp Mol Pathol 2005;79:126–135.
37. Okazaki Y, Ohno H, Takase K, et al. Cell surface expression of calnexin, a molecular chaperone in the endoplasmic reticulum. J Biol Chem 2000;275:35751–35758.
38. Yanase K, Madaio MP. Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J Autoimmun 2005;24:145–151.
39. Yanase K, Smith RM, Puccetti A, et al. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997;100:25–31.
40. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016;87:1038–1044.
41. Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53–63.
42. Lee H-K, Rocnik E, Fu Q, et al. Foxo/atrogin induction in human and experimental myositis. Neurobiol Dis 2012;46:463–475.
43. Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012;303:E410–E421.
44. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009;20:604–612.
45. Kostek MC, Nagaraju K, Pistilli E, et al. IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskelet Disord 2012;13:106.
46. De Larichaudy J, Zufferli A, Serra F, et al. TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet Muscle 2012;2:2.
47. Muller FL, Song W, Jang YC, et al. Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol 2007;293:R1159–R1168.
48. Abrigo J, Rivera JC, Simon F, et al. Transforming growth factor type beta (TGF-β) requires reactive oxygen species to induce skeletal muscle atrophy. Cell Signal 2016;28:366–376.
49. Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor-α causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000;102:1690–1696.
50. Supinski GS, Callahan LA. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol 2007;102:2056–2063.
51. Byun HS, Won M, Park KA, et al. Prevention of TNF-induced necrotic cell death by rottlerin through a Nox1 NADPH oxidase. Exp Mol Med 2008;40:186–195.
52. Trapani L, Segatto M, La Rosa P, et al. 3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration. J Cell Biochem 2012;113:2057–2063.
53. Mueller TD, Zhang J-L, Sebald W, Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta 2002;1592:237–250.